Test a blood-test signature to predict benralizumab benefit
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 75, and you have severe asthma requiring high-dose inhaled steroid plus another controller and/or steroid tablets
- Your lung function test in the past showed a big improvement after treatment (FEV1 improves by at least 12%, and by at least 200 mL)
- Your asthma control is not great (ACQ-7 score of 1.5 or higher), and you’ve had at least 3 flare-ups in the last year
- Your blood eosinophils are high enough (at least 0.3 G/L), or if they’re lower then you must meet an “eosinophilic” backup test such as high FeNO or high eosinophils in sputum
- You must not be a current smoker (and not a heavy former smoker), and you must not have an asthma flare at the start of the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well different biologic treatments work for people with severe or mild-to-moderate asthma, and compares them to healthy volunteers. It aims to find which treatments work best for different asthma types.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
This study tests a new way to take asthma medicine using a device that tracks your inhaler use. If you already use Fasenra (benralizumab) for severe asthma, you may be able to join.
This trial tests an experimental medication called SIM0718 to see if it can improve asthma control and reduce flare-ups. It may be an option for people whose asthma is not well-controlled with their current inhaler therapy.
This trial tests an add-on medicine called GB-0895 for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve breathing.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
Hear when a new Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.